Feedback
Settings

Settings

Goto Application

662,200 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12Q

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 66,220
1.WO/2025/257752METHODS FOR THE DETECTION OF CIRCULATING MICROCLOTS AND NEUTROPHIL EXTRACELLULAR TRAPS IN INFLAMMATORY CONDITIONS
WO - 18.12.2025
Int.Class G01N 33/564
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
564for pre-existing immune complex or autoimmune disease
 Appl.No PCT/IB2025/055967 Applicant UNIVERSITE DE MONTPELLIER Inventor THIERRY, Alain R
This invention relates to methods of detecting inflammatory disease in a subject by detecting circulating microclots, based on combined detection or co-detection of fibrin amyloid microclots and components from Neutrophil Extracellular Traps in a sample from the subject, wherein an increased presence of fibrin amyloid microclots and NETs in the sample compared to a control or reference value is indicative of inflammatory disease in the subject. The invention also relates to kits for detecting circulating microclots to be used in the methods of detecting inflammatory disease.
2.WO/2025/258997MICROFLUIDIC DROPLET REACTOR, METHODS FOR DETECTING EXTRACELLULAR VESICLE AND DIAGNOSING CANCER USING SAME, AND DETECTION KIT COMPRISING SAME
WO - 18.12.2025
Int.Class B01L 3/00
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
3Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
 Appl.No PCT/KR2025/007983 Applicant LABSPINNER INC. Inventor CHO, Yoon-kyoung
The present invention relates to a microfluidic droplet reactor which can be used for experiments and diagnosis by reacting a small amount of a sample in the form of fine droplets, and provides a microfluidic droplet reactor which introduces nanoparticles to fuse droplets, comprising: two aqueous-phase channels; one oil-phase channel; a junction where nanoparticles form microfluidic droplets; and an output channel connected to the junction.
3.WO/2025/256506BIOMARKERS FOR NEURODEGENERATIVE DISEASES
WO - 18.12.2025
Int.Class G16B 40/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
40ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
 Appl.No PCT/CN2025/100073 Applicant THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY Inventor IP, Nancy Yuk Yu
Provided herein are plasma protein markers associated with neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD), diagnostic and treatment/management methods for these conditions, as well as kits for diagnosing and/or treating/monitoring these conditions. Machine learning systems and methods are also provided for assessing the risk for a subject having a neurodegenerative disease based on measured protein marker levels.
4.WO/2025/258291GENETIC TEST METHOD AND GENETIC TEST KIT FOR T CELL RECEPTOR (TCR) OR B CELL RECEPTOR (BCR)
WO - 18.12.2025
Int.Class C12Q 1/6869
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6869Methods for sequencing
 Appl.No PCT/JP2025/017194 Applicant HITACHI, LTD. Inventor TANAKA, Junko
The present invention provides a genetic test method and a genetic test kit for immune cells in blood. Specifically, the present invention provides a genetic test method and a genetic test kit for analyzing a variable region of a T cell receptor (TCR) or a B cell receptor (BCR) in a single cell analysis technique.
5.WO/2025/259791COMPOSITIONS AND METHODS FOR TNPB AND ΩRNA MEDIATED TARGETING
WO - 18.12.2025
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/US2025/033213 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor DOUDNA, Jennifer A.
Provided are variant TnpB proteins that include an amino acid sequence having one or more amino acid substitutions relative to a corresponding wild type TnpB protein. Also provided are variant TnpB ωRNAs that include: a first nucleotide sequence (that includes one or more mutations relative to a corresponding wild type TnpB ωRNA) that can form a complex with a TnpB protein, and a second nucleotide sequence that can hybridize to a target sequence of a target nucleic acid, thereby guiding the complex to the target sequence. Methods of use are also provided.
6.WO/2025/259911DETERMINATION OF PARTICULATE CONTAMINANTS IN PARTICLES AND COMPOSITIONS
WO - 18.12.2025
Int.Class C12Q 1/37
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
34involving hydrolase
37involving peptidase or proteinase
 Appl.No PCT/US2025/033409 Applicant ELEKTROFI, INC. Inventor KRISHNA, Aditya
Provided herein are methods of detecting particulate contaminants in particles or a composition comprising particles, wherein the particles comprise a therapeutic or diagnostic agent, and wherein the particulate contaminants do not comprise the therapeutic or diagnostic agent.
7.WO/2025/257247AUTOMATED PCR ANALYZER
WO - 18.12.2025
Int.Class G01N 21/64
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
63optically excited
64Fluorescence; Phosphorescence
 Appl.No PCT/EP2025/066230 Applicant ROCHE DIAGNOSTICS INTERNATIONAL AG Inventor TROGER, Joerg
An automated polymerase chain reaction (PCR) analyzer (110) for analyzing at least one sample (112) and a method of automated PCR analysis is disclosed. The automated PCR analyzer (110) comprises: - at least one controller (114); - at least one thermocycling apparatus (116) configured for subjecting the sample (112) to at least one temperature modulation controlled by the controller (114); and - at least one photometer (118) configured for detecting at least one optically detectable property of the sample (112), the photometer (118) comprising at least one excitation light source (120) configured for illuminating the sample (112) with excitation light (122), the photometer (118) further comprising at least one photodetector unit (124) configured for detecting light (123) emitted from the sample (112), the photometer (118) further comprising a movable filter cell (126) controllable by the controller (114), the movable filter cell (126) comprising a plurality of filter cell units (128), each filter cell unit (128) comprising at least one optical excitation filter element (130), at least one dichroic filter (132), at least one optical detection filter element (134) and at least one the aperture stop (174), wherein the photometer (118) comprises a working position for the filter cell units (128), wherein the movable filter cell (126) is configured for selectively positioning a selected filter cell unit (128) selected from the plurality of filter cell units (128) in the working position, wherein, in the working position, the selected filter cell unit (128) is positioned such that the excitation light (122) interacts with the optical excitation filter element (130), the dichroic filter (132) and the aperture stop (174) of the selected filter cell unit (128) and that the light (123) emitted from the sample (112) interacts with the dichroic filter (132), the aperture stop (174) and the optical detection filter element (134) of the selected filter cell unit (128).
8.WO/2025/257787IN VITRO METHOD FOR THE DETERMINATION OF SUBJECTS AFFECTED BY A PATHOLOGY WHOSE AFFECTED CELLS INCREASE THE EXPRESSION OF NIS FOLLOWING ADMINISTRATION OF A COMPOUND
WO - 18.12.2025
Int.Class G01N 33/574
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
 Appl.No PCT/IB2025/056037 Applicant ISTITUTI CLINICI SCIENTIFICI MAUGERI SPA SB Inventor ROTONDI, Mario
The invention relates to an in vitro method for the determination in a subject affected by a pathology characterised by the expression of the Na/I symporter (NIS) in the affected cells, of whether the affected cells of the subject increase the expression of NIS following administration of the compound of formula (I), or enantiomers thereof, or pharmaceutically acceptable salts thereof: Formula (I) the method comprising the steps of: a) preparing a cell primary culture from a biological tissue sample comprising the affected cells of the subject affected by the pathology characterised by the expression of the Na/I symporter (NIS) in the affected cells; b) incubating at least a part of the cell primary culture with the compound of formula (I), or enantiomers thereof, or pharmaceutically acceptable salts thereof; c) determining a value A for the basal expression of NIS in said cell primary cultures of step a); and determining a value B for the expression of NIS in said cell primary culture following incubation step b); and determining a value B for the expression of NIS in said cell primary culture following incubation step b); and d) comparing value A and value B, wherein if value B is greater than value A, then the affected cells of said subj ect increase the expression of NIS following administration of the compound of formula ( I ), or enantiomers thereof, or pharmaceutically acceptable salts thereof. The invention also relates to a kit comprising RT-PCR primers, culture reagents and the compound of formula ( I ), or enantiomers thereof, or pharmaceutically acceptable salts thereof and to a kit comprising one or more antibodies for immunocytochemistry, culture reagents and the compound of formula ( I ), or enantiomers thereof, or pharmaceutically acceptable salts thereof; and their use in the above in vitro method.
9.WO/2025/258687PAN-CANCER NUCLEIC ACID THERAPEUTIC
WO - 18.12.2025
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
 Appl.No PCT/JP2025/021484 Applicant NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM Inventor KANDA Mitsuro
The present invention provides an inhibitor capable of inhibiting the expression of PCDHA11 and inhibiting the function of PCDHA11. Specifically, the present invention provides nucleic acid molecules such as siRNA or antisense nucleic acids that inhibit PCDHA11 expression. These inhibitors are effective against gastric cancer, pancreatic cancer, breast cancer, esophageal squamous cell carcinoma, lung adenocarcinoma, colon cancer, and the like, and can be used as pan-cancer therapeutics.
10.WO/2025/258565ORAL COMPOSITION
WO - 18.12.2025
Int.Class A23L 33/135
AHUMAN NECESSITIES
23FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; PREPARATION, TREATMENT OR PRESERVATION THEREOF
LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
33Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
10using additives
135Bacteria or derivatives thereof, e.g. probiotics
 Appl.No PCT/JP2025/020861 Applicant EZAKI GLICO CO., LTD. Inventor BABA, Yuhei
The purpose of the present invention is to provide an oral composition capable of improving the basal metabolic rate. The present invention can improve the basal metabolic rate by combining bifidobacteria with water-soluble dietary fibers.
# -